JP2001516727A - 新生物または癌性増殖の治療用もしくは造血の修復または作用促進用の相乗組成物および方法 - Google Patents

新生物または癌性増殖の治療用もしくは造血の修復または作用促進用の相乗組成物および方法

Info

Publication number
JP2001516727A
JP2001516727A JP2000511527A JP2000511527A JP2001516727A JP 2001516727 A JP2001516727 A JP 2001516727A JP 2000511527 A JP2000511527 A JP 2000511527A JP 2000511527 A JP2000511527 A JP 2000511527A JP 2001516727 A JP2001516727 A JP 2001516727A
Authority
JP
Japan
Prior art keywords
cancer
antigen
oil
mutant
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000511527A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001516727A5 (enExample
Inventor
ナビル・ハンナ
ゲイリー・アール・ブラスロースキー
カンダサミー・ハリハラン
Original Assignee
アイデック・ファーマシューティカルズ・コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイデック・ファーマシューティカルズ・コーポレイション filed Critical アイデック・ファーマシューティカルズ・コーポレイション
Publication of JP2001516727A publication Critical patent/JP2001516727A/ja
Publication of JP2001516727A5 publication Critical patent/JP2001516727A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000511527A 1997-09-18 1998-09-17 新生物または癌性増殖の治療用もしくは造血の修復または作用促進用の相乗組成物および方法 Pending JP2001516727A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93335997A 1997-09-18 1997-09-18
US08/933,359 1997-09-18
PCT/US1998/018495 WO1999013912A1 (en) 1997-09-18 1998-09-17 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis

Publications (2)

Publication Number Publication Date
JP2001516727A true JP2001516727A (ja) 2001-10-02
JP2001516727A5 JP2001516727A5 (enExample) 2006-03-02

Family

ID=25463798

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000511527A Pending JP2001516727A (ja) 1997-09-18 1998-09-17 新生物または癌性増殖の治療用もしくは造血の修復または作用促進用の相乗組成物および方法

Country Status (18)

Country Link
US (4) US20010018054A1 (enExample)
EP (1) EP1015031A4 (enExample)
JP (1) JP2001516727A (enExample)
KR (1) KR100540267B1 (enExample)
CN (1) CN1234413C (enExample)
AR (1) AR013012A1 (enExample)
AU (1) AU742216B2 (enExample)
CA (1) CA2303178A1 (enExample)
CO (1) CO4790100A1 (enExample)
IL (2) IL134937A0 (enExample)
IN (1) IN190792B (enExample)
MY (1) MY131805A (enExample)
NO (1) NO20001413L (enExample)
RU (1) RU2219947C2 (enExample)
SA (1) SA98190719B1 (enExample)
TW (1) TWI252108B (enExample)
WO (1) WO1999013912A1 (enExample)
ZA (1) ZA988461B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505666A (ja) * 2010-11-18 2014-03-06 ザ ジェネラル ホスピタル コーポレイション 癌治療のための降圧剤の組成物および使用

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
MXPA02008361A (es) * 2000-02-28 2004-05-17 Genesegues Inc Sistema y metodo de encapsulacion de nanocapsulas.
US7244232B2 (en) * 2001-03-07 2007-07-17 Biomed Solutions, Llc Process for identifying cancerous and/or metastatic cells of a living organism
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
HUP0600340A3 (en) * 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
EP2204190A1 (en) 2003-07-15 2010-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
EP1649020B1 (en) * 2003-07-21 2017-01-11 MSD Italia S.r.l. Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
EP1776459A1 (en) * 2004-08-03 2007-04-25 Transtech Pharma, Inc. Rage fusion proteins and methods of use
ES2473587T3 (es) 2004-08-03 2014-07-07 Transtech Pharma, Inc. Proteínas de fusión de RAGE y métodos de uso
EP1963786B1 (en) * 2005-12-23 2013-07-24 GCoder Systems AB Positioning pattern
WO2007094926A2 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
EA017291B1 (ru) 2006-05-05 2012-11-30 Транстек Фарма, Инк. Белки слияния на основе rage, их композиции и способы их применения
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
US8957031B2 (en) * 2007-10-23 2015-02-17 Regents Of The University Of Colorado, A Body Corporate Competitive inhibitors of invariant chain expression and/or ectopic clip binding
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
PH12012500564A1 (en) * 2009-10-09 2012-10-22 Sanofi Sa Polypeptides for binding to the receptor for advanced glycation endproducts as well as compositions and methods involving the same
US9782452B2 (en) * 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
SG10201902499VA (en) 2014-09-03 2019-04-29 Genesegues Inc Therapeutic nanoparticles and related compositions, methods and systems
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
KR20200130709A (ko) 2018-03-06 2020-11-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 전립선-특이 막 항원 car 및 이의 사용 방법
CN114814223A (zh) * 2022-04-20 2022-07-29 昆明市妇幼保健院 一种用于监测及控制疟原虫治疗的系统及设备

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052A (en) * 1845-05-13 Tktjss
US20020004052A1 (en) * 1990-05-08 2002-01-10 David Berd Composition comprising a tumor cell extract and method of using the composition
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
IE922436A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Induction of cytotoxic t-lymphocyte responses
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
AU669256B2 (en) 1992-10-29 1996-05-30 Celtrix Pharmaceuticals, Inc. Uses of TGF-beta receptor fragment as a therapeutic agent
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5932212A (en) * 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014505666A (ja) * 2010-11-18 2014-03-06 ザ ジェネラル ホスピタル コーポレイション 癌治療のための降圧剤の組成物および使用

Also Published As

Publication number Publication date
NO20001413D0 (no) 2000-03-17
US20010019715A1 (en) 2001-09-06
US6998125B2 (en) 2006-02-14
MY131805A (en) 2007-09-28
US20060153848A1 (en) 2006-07-13
RU2219947C2 (ru) 2003-12-27
NO20001413L (no) 2000-05-18
US20010018054A1 (en) 2001-08-30
IN190792B (enExample) 2003-08-23
CO4790100A1 (es) 1999-05-31
AR013012A1 (es) 2000-11-22
CN1279616A (zh) 2001-01-10
WO1999013912A1 (en) 1999-03-25
US20040137014A1 (en) 2004-07-15
AU9565898A (en) 1999-04-05
AU742216B2 (en) 2001-12-20
TWI252108B (en) 2006-04-01
EP1015031A4 (en) 2004-03-17
CN1234413C (zh) 2006-01-04
CA2303178A1 (en) 1999-03-25
EP1015031A1 (en) 2000-07-05
SA98190719B1 (ar) 2006-08-06
IL134937A0 (en) 2001-05-20
ZA988461B (en) 1999-03-30
KR100540267B1 (ko) 2006-01-10
KR20010024109A (ko) 2001-03-26
HK1033653A1 (en) 2001-09-14
IL134937A (en) 2008-04-13

Similar Documents

Publication Publication Date Title
AU742216B2 (en) Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
AU765822B2 (en) CD40 binding molecules and CTL peptides for treating tumors
JP2016537417A (ja) 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び／またはアゴニストにより癌を治療するための組み合わせ療法
US11235043B2 (en) Vaccines against antigens involved in therapy resistance and methods of using same
CN102170908A (zh) 向个体的肿瘤引流淋巴结递送cd40激动剂
TW201938793A (zh) 一種新型疫苗佐劑
JP2022046617A (ja) 異種ポリペプチドを含むＣｙａＡベースのキメラタンパク質及び免疫応答の誘導におけるその使用
Moeini et al. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine
KR101810840B1 (ko) 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp)
WO2017177907A1 (zh) 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
Mohit et al. The contribution of NT‐gp96 as an adjuvant for increasing HPV16 E7‐specific immunity in C57BL/6 mouse model
JP2022513438A (ja) Ｈｉｖワクチン免疫原
CN114790248B (zh) MUC1-PDL1-IgG1 Fc肿瘤疫苗及其制备方法和应用
HK1033653B (en) Synergistic composition and use thereof
US8367069B2 (en) Cytotoxic T cell defined EGFR peptide and an optimized derivative peptide
TWI398262B (zh) 腫瘤相關抗原之免疫性肽類及其於癌症治療上的用途
WO2025247278A1 (en) Circular rna-based therapeutic vaccine for treating solid tumor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081014

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090714